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In South Africa (SA), cervical cancer is diagnosed in 
>7  700 women each year, with >4  000 women dying 
annually of the disease.[1] Cervical cancer is caused 
by human papillomavirus (HPV) infection, the most 
common viral infection of the reproductive tract.[2] More 
than 190 types of HPV have been identified; these are classified as high- or 
low-risk groups, depending on their potential to cause cancerous lesions.[2]
HPV infection results in a number of conditions in males and 
females, ranging from precancerous lesions to those that become 
cancerous.[2] While the majority of HPV infections may result in 
spontaneous resolution without symptoms or disease, persistent 
infection with high-risk types may result in disease.[2] In women, 
persistent infection with HPV high-risk types 16 and 18 may lead to 
precancerous lesions, which if left untreated may progress to cervical 
cancer. For males and females, 90% of all cases of anogenital warts 
are caused by HPV high-risk types 6 and 11.[2] HIV-positive women 
have a higher prevalence and persistence of HPV infections, with an 
increased progression to cervical cancer.[2]
Cervical HPV infection is diagnosed using tests based on HPV-
DNA performed on cervical or vaginal swabs. Routine screening is 
done by cytology or visual inspection of the cervix by staining with 
acetic acid. HPV-induced changes in cervical epithelium are detected 
by the Papanicolaou (Pap) test. Precancerous lesions are treated by 
cryotherapy or surgical excision of the affected areas.[2]
In SA, there are currently two vaccines registered for the prevention 
of HPV-related disease: a quadrivalent vaccine (against HPV types 6, 
11, 16 and 18 (Gardasil)) and a bivalent vaccine (against HPV types 16 
and 18 (Cervarix)).[2] Both vaccines are intended for prophylactic use – 
before the onset of sexual activity and exposure to HPV.[2] 
The quadrivalent vaccine is indicated for use in females and males 
≥9 years of age.[2] It can be administered according to a 3-dose (0, 2, 
6 months) or 2-dose (0 and 6 months) schedule. The second dose 
should be given a minimum of 1 month after the first dose, and 
the third dose a minimum of 3 months after the second dose.[2] The 
bivalent vaccine is indicated for use in males and females ≥9 years 
of age. The recommended dosing schedule is 0 and 6 months. The 
second dose can be given between 5 and 7 months after the first 
dose.[2] The need for booster doses for either the quadrivalent or 
bivalent vaccines has not been established. Both vaccines should 
be administered intramuscularly (0.5 mL) in the deltoid region.[2] 
The vaccines should be stored in a refrigerator (2 - 8oC) and should 
not be frozen.[2] Neither vaccine contains live biological products 
and are non-infectious; they also do not contain any preservative 
agents.[2] Studies have shown that both vaccines are safe and highly 
immunogenic after administration. Current evidence indicates that 
the 2-dose schedule in females (9 - 14 years) is non-inferior to the 
3-dose schedule.[2] The vaccines have been shown to be safe and 
immunogenic –  also in HIV-positive individuals.[2]
Countries such as the USA, Australia, the UK, Canada and 
France offer HPV vaccination as part of a national immunisation 
programme.[3] In SA, historically, there has been a limited uptake of 
the HPV vaccine in the private sector, where estimates indicate that 
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approximately 50 000 individuals may have been vaccinated with the 
HPV vaccine between 2009 and 2014.[4] Contributory factors may 
have been the high cost of the vaccines (approximately ZAR650 per 
dose of vaccine), and a paucity of knowledge and awareness around 
cervical cancer and HPV, and vaccine availability among healthcare 
workers and patients.[4]
HPV demonstration project in 
KwaZulu-Natal 
An HPV demonstration project was conducted among 963 female 
learners (9 - 12 years) in rural KwaZulu-Natal (KZN) and showed a 
high uptake of the vaccine, using the delivery model of school health 
teams. The uptake of the vaccine was 99.7%, 97.9% and 97.8% for the 
first, second and third doses, respectively.[5] 
The high level of HPV vaccine delivery and uptake seen in 
this demonstration project is most likely owing to a combination 
of factors. Firstly, there was intensive communication with and 
education of all stakeholders, including the Department of Health 
(DOH) and the Department of Education (DOE) at national, 
provincial and district level, school governing bodies, parents, 
learners, educators, healthcare workers, community leaders and the 
media prior to initiating vaccination. Community engagement and 
mobilisation was an integral part of this process, as was the role of 
the media in promoting awareness. Secondly, there was emphasis on 
obtaining informed consent from parents or guardians in a timely 
manner so that questions and concerns with regard to the safety 
and other long-term effects could be satisfactorily addressed. The 
third factor involved the optimisation of aspects of the healthcare 
system considered crucial to the success of the vaccination project. 
These included the leadership of members of the DOH and DOE, the 
project team, management of the human resource capacity (including 
training of the existing school health teams), and partnerships 
that existed between different government departments and the 
community, and between public and the private sectors. Other key 
aspects of the healthcare system included information management, 
which was important in terms of monitoring delivery, uptake and 
adverse events, and management of the cold chain and infrastructure.[5]
The high vaccine uptake observed in this HPV demonstration 
project is comparable to findings from other studies.[6-8] A school-
based HPV vaccination programme in Brazil also found high rates 
of vaccine uptake – 87.5%, 86.3% and 85.0% for the three doses, 
respectively.[6] A multicountry study of vaccination programmes in 
Peru, Uganda, Vietnam and India showed a high coverage in school-
based programmes in the first 3 countries (>80%).[7] In India, where a 
set of mixed strategies were used (school-based healthcare centres and 
community campaigns), coverage varied between 68.4% and 87.8%, 
depending on the populations targeted.[7] 
A study of the vaccination of 87 000 girls (9 - 18 years) in 7 low-
income countries (Bhutan, Bolivia, Cambodia, Cameroon, Haiti, 
Lesotho and Nepal) using school-based strategies, health facility 
approaches, and combination school and facility models found a 
range of coverage rates depending on the delivery model.[8] Overall, 
for all the countries, the model using the health facility alone had a 
coverage of 77%, while the school-based and combination strategies 
had a coverage >90%.[8] While school-based programmes have 
generally exhibited high uptake or coverage rates, the opposite has 
been shown in non-school-based programmes. 
In the USA, which uses a non-school-based model, coverage 
has been reported as 35% for all 3 doses.[9] HPV vaccination was 
introduced into the routine immunisation schedule in 2006 for 
girls 11 or 12 years old, with a recommendation for catch-up doses 
in females aged 13 - 26 years.[10] In 2011, routine vaccination of 
males in the same age groups as the female target population was 
recommended. The vaccine type HPV prevalence decreased by >50% 
(from 11.5% to 5.1%).[10] The US Centers for Disease Control and 
Prevention (CDC) highlighted three areas to be addressed to improve 
the HPV vaccination coverage: the education of parents, as many do 
not understand the need for the vaccine or have concerns over its 
safety; healthcare providers who will be involved in recommending 
the vaccine – some are less likely to recommend the HPV vaccine 
than they would other vaccines; and the need to reduce missed 
opportunities for vaccination during healthcare visits.[9]
Experiences from HPV vaccine demonstration projects in other 
countries have shown that public messaging around cervical cancer, 
HPV, and the HPV vaccine has an important impact on the 
acceptability and effectiveness of vaccination programmes.[6-8] The 
success of the vaccination programme in Brazil is attributed to the 
school-based advertising strategy and the role of the media.[6] The 
information disseminated in schools played a significant role in the 
parents consenting to vaccinate their children. Also, the learners had 
an important part in actively conveying information from schools to 
their homes.[6-8]
A report of a school-based HPV vaccination programme in Peru 
highlighted the feasibility of using the existing resources in the 
healthcare system.[11] Key elements related to the preparedness of the 
healthcare system were human resources, training, cold chain and 
infrastructure, and the recording and reporting of vaccinations.[11] The 
facilitating factors were planning, co-ordination between education 
and health, facilitation between levels of the healthcare system, 
training, and comprehensive community awareness strategies.[11]
DOH roll-out of HPV vaccines in 
schools 
In April 2014, the SA DOH launched the national school-based HPV 
vaccination programme for Grade 4 (≥9 years old) female learners 
attending public schools, with a target population of an estimated 
500 000 learners.[12] A 2-dose strategy was adopted, using the bivalent 
vaccine (Cervarix).[12] The vaccination programme has been included 
in the Extended Programme on Immunisation (EPI).[12] Prior to 
the commencement of the vaccination process, the Department of 
Basic Education (DBE) released a Guide for Educators, and made 
available vaccination consent forms, letters to parents and caregivers, 
and promotional material.[12] Unpublished preliminary data indicate 
that the coverage is >90% for both the first and second rounds of 
vaccination.[4]
Implications for the primary 
healthcare provider
Despite the HPV vaccine being rolled out through the school health 
teams to female learners in Grade 4 (≥9 years), it is anticipated that 
some learners may miss the opportunity to be vaccinated because 
the vaccine is offered to public school learners only. Other learners 
may miss vaccination owing to absenteeism or no access to school 
health teams.[13] This affords the primary healthcare practitioner the 
opportunity to contribute towards primary prevention of cervical 
cancer. Essential to this is the ability to identify girls who are eligible 
for the HPV vaccination school programme but have missed the 
opportunity, and to provide appropriate counselling to their parents. 
A clinical algorithm (Fig. 1) is outlined, which may be of use to the 
practising general practitioner or primary healthcare provider.
The Children’s Act 38 of 2005 provides for a child ≥12 years of 
age with sufficient emotional and mental maturity, who is able to 
comprehend the risks and benefits of treatment, and can consent to 
medical treatment without consent from a parent or guardian.[14] The 
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implication is that a child ≥12 years meeting 
these criteria can independently consent to 
HPV vaccination. However, children <12 years 
require parental consent; the DBE provides 
information and forms for parents to sign 
before the visit by school health teams. 
Case vignette
A 9-year-old girl is asked to get her parents 
to sign consent forms for the administration 
of the HPV vaccine. The forms are signed by 
the mother and the child is administered the 
vaccine 2 days later when the school health 
team visits the school. Subsequently, the child 
develops a fever for a few days, which resolves 
spontaneously. The parents are upset and 
approach the school for an explanation. The 
parents state that they were not informed of 
this possible side-effect of the vaccine. 
Learning point: It is important to note that 
signing the consent form may not necessarily 
imply informed consent; therefore, it is 
important that members of the public are 
given the opportunity to ask questions about 
the intervention. The Health Professions 
Council of South Africa (HPCSA) states 
that the legal requirements for proper 
informed consent in SA should include the 
following:
• ‘Knowledge of the nature or extent of the 
harm or risk;
• Appreciated and understood the nature of 
the harm or risk;
• Consented to the harm or assumed the 
risk; and
• The consent must have been comprehensive 
(i.e. extended to the entire transaction, 
inclusive of its consequences).’[15]
Recommendations 
for private healthcare 
providers to increase 
awareness and improve 
uptake of HPV vaccination 
among adolescents
In view of the demonstrated success of 
vaccinating learners in a school-based HPV 
vaccination delivery model, it is recommended 
that the private sector increase knowledge 
and awareness around cervical cancer, HPV 
and the need for HPV vaccination, especially 
in adolescents. This strategy should be viewed 
as part of a country-wide comprehensive 
programme for cervical cancer prevention 
and control that targets girls and women 
across each stage of their life course. 
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Identify girl/woman eligible for
the HPV vaccine (9 - 26 years of
age). If yes:
Is the client in Grade 4, and
≥9 years? Does the client qualify
for vaccination by the
school health team?
If yes to both questions, ask the
parent to discuss HPV
vaccination roll-out at the local
school with the school secretary
If the client is not eligible for the school
health vaccination programme consider
the following:
Does the client have a medical aid that
will pay for the vaccine?
Can the client/parents aord to pay for
the vaccine?
If yes to either of the questions: Obtain
informed consent from parent or client
>12 years who is able to comprehend 
the implications of the vaccination
Perform the vaccination at 0 and 6+
months
Fig. 1. Clinical algorithm for healthcare providers.
